Worth reading
37Immaterial
Scored from 5 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
15.5
Year-on-year change in revenue (%)Wording
Conditional
How definitive the wording is.Results for this period
First quarter1 December 2025–28 February 2026ConsolidatedJapanese GAAPNet Sales16,557¥ millionYear on year +15.5%Progress 24.3%
Operating profit1,152¥ millionYear on year +11.7%Progress 33.9%
Ordinary income1,079¥ millionYear on year +3.6%Progress 32.7%
Net income attributable to owners of the parent586¥ millionYear on year +16.0%Progress 24.9%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥14.52
Financial position at period-end
Total assets73,309¥ million
of which net assets 27,880 ¥ millionEquity ratio 37.6%vs. prior year-end +1.7pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Segment revenueFine chemicals ¥5,125 million (YoY -8.7%), HBC & Food ¥5,504 million (YoY +49.8%), Pharmaceuticals ¥2,971 million (YoY +5.1%), Chemicals ¥2,928 million (YoY +32.6%), Other ¥28 million (YoY +239.3%)
Segment profitFine chemicals ¥214 million (YoY -41.3%), HBC & Food ¥265 million (YoY +27.5%), Pharmaceuticals ¥260 million (YoY -26.7%), Chemicals ¥376 million (YoY +177.3%), Other ¥-79 million
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥68,000 million (YoY +8.4%)
Operating profit¥3,400 million (YoY +12.7%)
Ordinary income¥3,300 million (YoY +13.4%)
Net income¥2,350 million (YoY +7.5%)
Revision to Earnings ForecastNo revision
Annual Dividend Forecast¥18 → ¥18（0.0%）
Factors Behind Changes in Business Performance
In addition to strong sales of imported cosmetics in the HBC & Food business, both the surface-treatment chemicals division and the surface-treatment equipment division in the Chemicals business performed well, resulting in growth in both net sales and profit.
Disclosure regarding the going concern assumption
No applicable matters.
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNo additions or exclusions (no material change in the scope of consolidation)
Material subsequent eventsNo applicable matters.
Impairment lossNot applicable (cumulative consolidated period for the first quarter under review)
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of investment securities ¥0 million / Extraordinary loss Losses on disposal of fixed assets ¥0 million
Depreciation and amortization¥543 million
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingNo
Issued Shares at Period-End41,097,566 Shares
Treasury Shares at Period-End757,889 Shares
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 December 2025–28 February 2026 |
| Net Sales | ¥16,557 million (YoY +15.5%) |
| Operating profit | ¥1,152 million (YoY +11.7%) |
| Ordinary income | ¥1,079 million (YoY +3.6%) |
| Profit attributable to owners of the parent | ¥586 million (YoY +16.0%) |
| Net income per share | ¥14.52 |
| Equity ratio | End of the current fiscal period 37.6 / End of previous period 35.9 |
| Total assets | ¥73,309 million |
| Net assets | ¥27,880 million |
| Full-year earnings forecast | Net Sales ¥68,000 million (YoY +8.4%) / Operating profit ¥3,400 million (YoY +12.7%) / Ordinary income ¥3,300 million (YoY +13.4%) / Net income ¥2,350 million (YoY +7.5%) |
| Revision to Earnings Forecast | No revision |
| Annual Dividend Forecast | ¥18 → ¥18（0.0%） |
| Segment revenue | Fine chemicals ¥5,125 million (YoY -8.7%), HBC & Food ¥5,504 million (YoY +49.8%), Pharmaceuticals ¥2,971 million (YoY +5.1%), Chemicals ¥2,928 million (YoY +32.6%), Other ¥28 million (YoY +239.3%) |
| Segment profit | Fine chemicals ¥214 million (YoY -41.3%), HBC & Food ¥265 million (YoY +27.5%), Pharmaceuticals ¥260 million (YoY -26.7%), Chemicals ¥376 million (YoY +177.3%), Other ¥-79 million |
| Depreciation and amortization | ¥543 million |
| Impairment loss | Not applicable (cumulative consolidated period for the first quarter under review) |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of investment securities ¥0 million / Extraordinary loss Losses on disposal of fixed assets ¥0 million |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | No additions or exclusions (no material change in the scope of consolidation) |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 41,097,566 Shares |
| Treasury Shares at Period-End | 757,889 Shares |
| Factors Behind Changes in Business Performance | In addition to strong sales of imported cosmetics in the HBC & Food business, both the surface-treatment chemicals division and the surface-treatment equipment division in the Chemicals business performed well, resulting in growth in both net sales and profit. |
Items this document does not state (9)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodPayout ratioShareholder Return PolicyRegional salesOrders received and order backlog
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Sales of imported cosmetics performed well in the HBC & Food business, while the surface-treatment chemicals and equipment divisions also performed well in the Chemicals business.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.